Mannitol
| Evidence Level: L5 | Predicted Indications: 52 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Mannitol |
| DrugBank ID | DB00742 |
| Brand Names (EU) | Bronchitol |
| Evidence Level | L5 |
| Predicted Indications | 52 |
| Top Prediction Score | 99.97% |
Approved Indication (EMA)
Bronchitol is indicated for the treatment of cystic fibrosis (CF) in adults aged 18 years and above as an add-on therapy to best standard of care.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | nephrogenic syndrome of inappropriate antidiuresis | 99.97% | DL |
| 2 | congestive heart failure | 99.90% | DL |
| 3 | acute pulmonary heart disease | 99.88% | DL |
| 4 | exercise-induced malignant hyperthermia | 99.86% | DL |
| 5 | malignant hyperthermia, susceptibility to | 99.80% | DL |
| 6 | familial periodic paralysis | 99.75% | DL |
| 7 | hypokalemic periodic paralysis | 99.72% | DL |
| 8 | congenital multicore myopathy with external ophthalmoplegia | 99.72% | DL |
| 9 | moderate multiminicore disease with hand involvement | 99.71% | DL |
| 10 | pseudotumor cerebri | 99.70% | DL |
| 11 | nephrogenic diabetes insipidus | 99.70% | DL |
| 12 | King-Denborough syndrome | 99.69% | DL |
| 13 | central core myopathy | 99.69% | DL |
| 14 | renal tubule disease | 99.68% | DL |
| 15 | Senior-Boichis syndrome | 99.65% | DL |
| 16 | psychomotor regression-oculomotor apraxia-movement disorder-nephropathy syndrome | 99.65% | DL |
| 17 | malignant hyperthermia of anesthesia | 99.62% | DL |
| 18 | intracranial hypertension | 99.59% | DL |
| 19 | RHYNS syndrome | 99.56% | DL |
| 20 | cranioectodermal dysplasia | 99.54% | DL |
Showing top 20 of 52 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.